Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: A phase II multicentre randomized double-blinded controlled trial

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1138-1144

  Prey, S ^a,b,c   Ezzedine, K ^a,b,c   Doussau, A ^b,d   Grandoulier, A S ^d   Barcat, D ^e   Chatelus, E ^f   Diot, E ^g   Durant, C ^h   Hachulla, E ⁱ   De Korwin Krokowski, J D ^j   Kostrzewa, E ^k   Quemeneur, T ^l   Paul, C ^m   Schaeverbeke, T ^b,d   Seneschal, J ^a,b,c   Solanilla, A ^a,b   Sparsa, A ⁿ   Bouchet, S ^b,d   Lepreux, S ^b,o   Mahon, F X ^b,d   Chene, G ^b,d   Taieb A ^a,b,c   more..

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Bordeaux Institute of Oncology   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e CHG R Boulin   (France)

^f UNIVERSITÉ DE STRASBOURG   (France)

^g CHU BRETONNEAU   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ UNIV LILLE   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k HAUT LÉVÊQUE HOSPITAL   (France)

^l Paul Sabatier University ^*  (France)

^m UNIVERSITÉ PAUL SABATIER   (France)

ⁿ DUPUYTREN UNIVERSITY HOSPITAL   (France)

^o HÔPITAL PELLEGRIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO;

ADULT; AGED; ARTHRITIS; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE SCLERODERMA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFECTION; LUNG FUNCTION TEST; MALE; MODIFIED RODNAN SKIN SCORE; MULTICENTER STUDY; MYALGIA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SCLERODERMA ASSOCIATED DIFFUSE SKIN FIBROSIS; SCORING SYSTEM; SKIN BIOPSY; SKIN EXAMINATION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; THORAX PAIN; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT; XEROSIS;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY OF LIFE; SCLERODERMA, DIFFUSE; SKIN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84868214290     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11186.x     Document Type: Article

References (18)

1. Harris ML, Rosen A,. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003; 15: 778-84.
2. Bujor AM, Asano Y, Haines P, et al. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 2011; 63: 1729-37.
3. Bonner JC,. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-73.
4. Distler JHW, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
5. Soria A, Cario-André M, Lepreux S, et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology (Basel) 2008; 216: 109-17.
6. Iwamoto N, Distler JHW, Distler O,. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr Rheumatol Rep 2011; 13: 21-7.
7. Hatano M, Yao A, Shiga T, et al. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010; 51: 272-6.
8. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
9. van Daele PLA, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008; 58: 2549-52.
10. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009; 60: 584-91.
11. Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008; 47: 735-7.
12. Moinzadeh P, Krieg T, Hunzelmann N,. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol 2010; 63: e102-4.
13. Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-6.
14. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011; 63: 3547-51.
15. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
16. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-10.
17. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
18. Bouchet S, Chauzit E, Ducint D, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011; 412: 1060-7.